The UPMC-backed cancer biotherapeutics developer priced its shares in the middle of their range in its initial public offering.

Werewolf Therapeutics, a US-based cancer treatment developer backed by healthcare provider UPMC and pharmaceutical firm Taiho, has raised $120m in an initial public offering on the Nasdaq Global Market. The company had initially filed to issue 6.25 million shares and set a price range between $15 and $17, but later upped the number of shares…

The rest of this content is only accessible to University Venturing: News, Data, and Events - Global University Venturing Subscribers.

This content is only accessible to subscribers. If you are a subscriber, please sign in. Otherwise, if you would like to try before you buy and haven't previously taken out a free trial, you can do so below. You can also see details on subscriptions by clicking the Subscription Options button.